Identifying new targets for reducing colorectal and endometrial cancer risk
Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction
This study is trying to find new ways to lower the risk of colorectal and endometrial cancer by looking at genetic information and family histories from patients who have been screened for these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06096688 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and store data, tissue samples, and personal and family histories from patients screened for colorectal and endometrial cancer at NYP and Weill Cornell Medicine. The study focuses on understanding the heritable components of these cancers by analyzing genomic and epigenetic profiles of patients with hereditary cancer syndromes and those with sporadic cases. Researchers will investigate gene expression and protein profiles in various tissues to discover novel mechanisms of carcinogenesis and identify potential targets for therapy and prevention.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with hereditary cancer syndromes, those undergoing endoscopic procedures for average-risk screening, and patients diagnosed with colorectal or endometrial cancer seeking treatment.
Not a fit: Patients without a hereditary cancer syndrome or those not undergoing relevant screening procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for cancer risk reduction and targeted therapies for patients with hereditary cancer syndromes.
How similar studies have performed: Other studies have shown success in identifying genetic predispositions and mechanisms in cancer, making this approach promising yet still novel in its specific focus on colorectal and endometrial cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
The following eligibility criteria must be met as follows: 1. Age ≥ 18 years old. 2. One of the following must be met: 1. Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR 2. Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR 3. Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR 4. Individuals coming to Weill-Cornell Medicine/NYPH for care such as, but not limited to, diagnostic testing, clinic and/or treatment visit. 3. Willingness and ability to sign informed consent. 4. Ability to read/understand English, Spanish, and/or simplified Chinese.
Where this trial is running
New York, New York
- NYP/Weill Cornell Medicine — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Steven M Lipkin, MD — Weill Medical College of Cornell University
- Study coordinator: Steven M Lipkin, MD, PhD
- Email: stl2012@med.cornell.edu
- Phone: 212-746-4014
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.